SAN Sanofi

Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Paris, February 13, 2025. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).

These documents are available on the company’s website:

In addition, the Form 20-F is available on the website of the SEC () and the “Document d’Enregistrement Universel” is available on the website of the AMF (). A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations

Sandrine Guendoul |  25 | 

Victor Rouault |  40 | 

Investor Relations

Thomas Kudsk Larsen | 93 |

Alizé Kaisserian | 11 |

Felix Lauscher | 9 |

Keita Browne | 6 |

Nathalie Pham | 17 |

Tarik Elgoutni | 7 |

Thibaud Châtelet | 90 |

Attachment



EN
13/02/2025

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE
Free
SAN SANOFI

Press Release: Dupixent sBLA accepted for FDA priority review for the ...

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision expected by June 20, 2025Priority review granted based on positive pivotal results demonstrating significant improvements in sustained disease remission with Dupixent compared to placeboBP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation chara...

18h / 11m 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : La FDA accorde un examen prioritaire à la deman...

Communiqué de presse : La FDA accorde un examen prioritaire à la demande de licence supplémentaire relative au Dupixent pour le traitement ciblé de la pemphigoïde bulleuse La FDA accorde un examen prioritaire à la demande de licence supplémentaire relative au Dupixent pour le traitement ciblé de la pemphigoïde bulleuse Si la demande est approuvée, le Dupixent sera le premier et le seul médicament ciblé pour le traitement de la pemphigoïde bulleuse aux États-Unis ; la décision de la FDA est attendue le 20 juin 2025.Examen prioritaire accordé sur la base des résultats positifs de l’étude pi...

18h / 11m 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Filing of the 2024 U.S. Form 20-F and French “Document ...

Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 13, 2025. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). These documents are available on the company...

February 13, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Update on extraintestinal pathogenic E. coli vaccine ph...

Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn’t demonstrate sufficient efficacy in preventing invasive E. coli diseaseNo safety signals related to the vaccine candidate were identified Paris, February 13, 2025. A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that...

February 13, 2025 1 EN
Free Trial
SAN SANOFI

Sanofi: 1 director

A director at Sanofi bought 1,000 shares at 106.230USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

02/07/25 February 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch